The increasing interest in potent weight management has resulted in considerable investigation into groundbreaking treatments. Lately , Retatrutide, a combined -action GIP and glucagon-like peptide-1 (GLP-1) receptor agonist , has demonstrated encouraging results in clinical trials, indicating potential for considerable weight decrease. Consequentl